PHARMXHEALTHONE MASTER CONSENT & TREATMENT AGREEMENT
(for Weight Loss + Peptides + Hormones + Exosome Therapy)
PHARMXHEALTHONE
MASTER PATIENT CONSENT & TREATMENT AGREEMENT
Nationwide Telehealth (Where Authorized) | Local In-Clinic Services
Medical Weight Management | Hormone Therapy | Peptide Consultations | IV/NAD+ Consultations | Regenerative Medicine Education
Last Revised: November 9, 2026
Version: 2.0 — Pending Clinical and Legal Approval
INTRODUCTION AND INFORMED CONSENT
This Master Patient Consent & Treatment Agreement (“Agreement”) explains the general nature of healthcare services offered by PharmXHealthOne (“PHO”), including potential benefits, risks, limitations, patient responsibilities, financial obligations, privacy practices, and telehealth arrangements.
By accepting this Agreement, I acknowledge that I have received information about the services for which I am being evaluated, have had an opportunity to ask questions, and voluntarily consent to the applicable evaluation and care described herein.
I understand that accepting this Agreement does not guarantee a diagnosis, prescription, procedure, treatment recommendation, or particular outcome. Specific medications, invasive procedures, investigational interventions, and other treatments may require separate informed consent.
This Agreement does not replace a provider's responsibility to obtain informed consent appropriate to the proposed treatment.
SECTION 1: PROGRAM OVERVIEW
PharmXHealthOne provides medical evaluations, education, monitoring, and clinically appropriate services through licensed healthcare professionals, subject to applicable federal and state requirements.
1.1 Medical Weight Management
Services may include medical history review, laboratory testing when indicated, body-composition assessment, nutrition and lifestyle counseling, medication evaluation, and ongoing monitoring.
FDA-approved medications, including certain semaglutide- and tirzepatide-containing products, may be considered when clinically appropriate and prescribed for an authorized indication or otherwise in accordance with applicable law.
Compounded medications may be considered only when legally permissible and supported by an individualized clinical determination. They are not FDA-approved and are not automatically interchangeable with FDA-approved products.
1.2 Peptide Consultations
PharmXHealthOne may provide education and clinical consultations concerning peptide-related therapies.
Certain substances marketed as peptides, including BPC-157, CJC-1295, Ipamorelin, TB-500, and MOTS-C, are not FDA-approved for routine human therapeutic use. Some present significant safety, quality, and regulatory concerns.
Discussion of these substances does not mean they are available, recommended, legally prescribable, or offered for administration by PharmXHealthOne.
Any peptide-related treatment must undergo separate clinical, pharmacy, and regulatory review before being considered.
1.3 Hormone Therapy
Hormone-related services may include evaluation of symptoms, medical history, appropriate laboratory results, and consideration of treatment options.
Depending on clinical circumstances, treatment may involve FDA-approved hormone medications or other legally permissible therapies.
Hormone therapy is not appropriate for every patient. Certain medications, including testosterone, are controlled substances and are subject to additional prescribing requirements.
1.4 Exosome and Regenerative Medicine Consultations
PharmXHealthOne may provide educational consultations regarding regenerative medicine research and the regulatory status of exosome products.
There are currently no FDA-approved exosome products for human therapeutic use.
Exosome products are not established as safe or effective treatments for disease, injury, aging, or general wellness.
This Agreement does not authorize exosome prescribing, purchasing, infusion, injection, or administration. Any participation in an authorized clinical investigation would require appropriate regulatory authorization and separate study-specific informed consent.
1.5 IV and NAD+ Consultations
PharmXHealthOne may evaluate patients for medically appropriate IV services and discuss NAD+ therapy, subject to applicable clinical and legal requirements.
NAD+ is a naturally occurring coenzyme involved in cellular metabolism. Its biological functions do not establish that administered NAD+ improves energy, cognitive performance, longevity, or other health outcomes.
The evidence for many proposed NAD+ applications remains limited or uncertain.
A consultation does not guarantee that NAD+ or another IV treatment will be recommended. Any proposed administration requires separate treatment-specific consent.
1.6 Telehealth and In-Clinic Services
Telehealth services are available only where PharmXHealthOne and the treating clinician are authorized to provide them.
In-person services are provided at authorized clinical locations, including the Boynton Beach, Florida clinic, as applicable.
SECTION 2: TELEHEALTH CONSENT
2.1 Consent to Telehealth
I voluntarily consent to receiving appropriate healthcare services through secure electronic communication technologies, which may include video consultations, telephone encounters, patient portals, and other legally permitted methods.
I understand that the communication method used must be appropriate for the clinical service and must satisfy applicable legal requirements.
2.2 Telehealth Limitations
I understand that telehealth may involve:
-
Technical interruptions or communication failures.
-
Limitations on physical examination.
-
Potential privacy or cybersecurity risks.
-
The need for additional laboratory testing or in-person evaluation.
-
Situations where a clinician cannot safely provide a diagnosis or treatment remotely.
2.3 Patient Responsibilities
I agree to provide accurate information regarding my identity, physical location during the encounter, medical history, medications, allergies, symptoms, and relevant health conditions.
I understand that my clinician may recommend in-person care or decline to provide treatment remotely when clinically necessary.
2.4 Emergencies
Telehealth services offered by PharmXHealthOne are not a substitute for emergency medical services.
If I experience a medical emergency, I should call 911 or seek immediate emergency care.
2.5 Right to Decline
I understand that I may decline or withdraw consent to telehealth services, subject to applicable laws and the availability of alternative care arrangements.
SECTION 3: STATE REGULATORY REQUIREMENTS
I acknowledge that healthcare delivery, telehealth, prescribing, laboratory testing, and pharmacy fulfillment are governed by applicable federal and state laws.
I understand that:
-
A provider must hold the appropriate license, registration, or authorization for the jurisdiction where I am physically located during the encounter.
-
Certain services may require an in-person examination or additional clinical assessment.
-
Controlled-substance prescriptions are subject to additional federal and state requirements.
-
Medication availability may vary based on applicable law, pharmacy eligibility, and clinical circumstances.
-
PharmXHealthOne may decline or discontinue a proposed service when it cannot be provided safely or lawfully.
I understand that nationwide telehealth availability does not mean every service or medication is available in every state.
SECTION 4: MEDICATION DISCLOSURES
4.1 FDA-Approved Medications
FDA-approved medications have undergone FDA review for safety, effectiveness, and quality for their approved uses.
Examples of FDA-approved products containing semaglutide or tirzepatide include Wegovy, Ozempic, Zepbound, and Mounjaro.
These products have different approved indications, prescribing information, warnings, and patient eligibility requirements.
4.2 Compounded Medications
I understand that compounded medications are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality.
Compounded semaglutide and compounded tirzepatide are different from FDA-approved products and should not be represented as FDA-approved, clinically equivalent, or interchangeable.
Compounding is permitted only under applicable federal and state legal conditions. The existence of a prescription or licensed pharmacy does not, by itself, establish that a particular compounded product is legally permissible.
4.3 Medication and Pharmacy Identification
Before a medication is dispensed or administered, I will be informed, as applicable, of:
-
The exact medication name and formulation.
-
Whether the product is FDA-approved or compounded.
-
The intended route of administration.
-
The prescribed dose and administration instructions.
-
The dispensing pharmacy's identity.
-
Relevant warnings, precautions, and monitoring requirements.
-
Material alternatives, including FDA-approved options when appropriate.
I may ask questions about the medication, pharmacy, and rationale for the proposed treatment.
4.4 Off-Label Prescribing
I understand that an FDA-approved medication may sometimes be prescribed for a use not specifically included in its FDA-approved labeling when clinically appropriate and legally permissible.
Off-label use of an FDA-approved medication is not the same as using an unapproved drug or investigational substance.
Off-label prescribing does not establish that a treatment is safe or effective for every proposed use.
4.5 Prescription Decisions
I understand that all prescribing decisions depend on individualized clinical evaluation.
A consultation, program enrollment, or payment does not guarantee that a prescription will be issued.
4.6 Pharmacy Fulfillment
Prescription processing, dispensing, delivery, and shipping may involve independent licensed pharmacies.
Pharmacy processing times, product availability, and shipping conditions may vary.
Any applicable medication cancellation or refund terms will be disclosed before the relevant charge or order is finalized.
SECTION 5: RISKS, SIDE EFFECTS, AND CONTRAINDICATIONS
I understand that all medications and medical interventions may involve risks and may not be appropriate for every patient.
5.1 Medical Weight Management Medications
Depending on the specific medication, potential risks may include:
-
Nausea, vomiting, diarrhea, constipation, or abdominal discomfort.
-
Dehydration and kidney injury.
-
Gallbladder complications.
-
Pancreatitis.
-
Hypoglycemia, particularly with certain other diabetes medications.
-
Serious allergic reactions.
-
Additional medication-specific contraindications and warnings.
Some GLP-1 medications carry boxed warnings concerning thyroid C-cell tumors observed in rodents, with uncertain relevance to humans.
I understand that the applicable FDA-approved prescribing information or medication-specific disclosures will be reviewed with me.
5.2 Peptide-Related Risks
For certain unapproved or investigational peptides, adequate human safety and effectiveness information may be unavailable.
Potential concerns may include allergic reactions, immune responses, contamination, impurities, dosing uncertainty, and unknown short- or long-term effects.
A discussion of potential risks does not authorize treatment with an unapproved peptide.
5.3 Hormone Therapy Risks
Depending on the medication and my medical history, potential risks may include:
-
Acne or skin changes.
-
Mood or sleep changes.
-
Fluid retention.
-
Changes in red blood cell counts.
-
Fertility or reproductive effects.
-
Blood-clotting or cardiovascular concerns.
-
Breast, uterine, prostate, or other organ-specific considerations.
The risks and monitoring requirements differ among hormone products and treatment regimens.
5.4 Exosome Products
I understand that there are no FDA-approved exosome products.
Potential safety concerns include immune reactions, contamination, infection, inflammatory responses, and serious or unknown adverse effects.
This Agreement does not constitute consent for exosome administration.
5.5 IV and NAD+ Services
Depending on the proposed product and route of administration, risks may include:
-
Pain, bruising, or irritation at the infusion site.
-
Infection or inflammation.
-
Allergic or infusion reactions.
-
Fluid-related complications.
-
Medication-specific adverse reactions.
-
Uncertain benefits and incompletely characterized risks.
Any IV procedure requires separate clinical assessment and appropriate informed consent.
5.6 Pregnancy, Breastfeeding, and Reproductive Health
I agree to inform my treating clinician if I am pregnant, planning pregnancy, breastfeeding, or believe I may be pregnant.
Certain medications may be contraindicated or require discontinuation before or during pregnancy.
I will promptly contact my clinician for individualized instructions rather than independently stopping all prescribed treatments without guidance.
SECTION 6: PATIENT RESPONSIBILITIES
I agree to:
-
Provide complete and accurate medical information.
-
Follow the prescribed medication and treatment instructions.
-
Attend clinically required follow-up appointments.
-
Complete recommended laboratory tests when necessary for safe care.
-
Report adverse effects, medication errors, and significant health changes promptly.
-
Avoid sharing prescription medications.
-
Avoid changing doses or combining treatments without clinical guidance.
-
Inform PharmXHealthOne about medications and supplements obtained elsewhere.
-
Maintain appropriate communication with my primary care provider and other treating clinicians.
I understand that failure to complete necessary safety monitoring may result in postponement or discontinuation of a treatment.
SECTION 7: RESULTS AND TREATMENT LIMITATIONS
I understand that individual responses to healthcare services vary.
PharmXHealthOne does not guarantee:
-
Weight loss or maintenance of weight loss.
-
Body-fat reduction or muscle gain.
-
Improvement in hormonal symptoms.
-
Hair restoration.
-
Increased energy or cognitive performance.
-
Reversal of aging.
-
Prevention or resolution of disease.
-
Any particular clinical or cosmetic result.
I understand that patient testimonials, photographs, educational examples, and marketing materials do not guarantee that I will experience similar results.
Clinical recommendations depend on my individual medical evaluation and the available evidence.
SECTION 8: SERVICE AVAILABILITY
8.1 Telehealth Services
Where legally authorized and clinically appropriate, telehealth may include:
-
Medical weight-management evaluations.
-
Medication management.
-
Hormone-related consultations.
-
Diabetes and metabolic-health education.
-
Follow-up and monitoring.
-
Other appropriate clinical consultations.
Not every medication or service is available in every jurisdiction.
8.2 In-Person Services
At authorized locations, PharmXHealthOne may provide:
-
Clinical examinations and assessments.
-
Body-composition evaluations.
-
Certain IV services.
-
Device-based or body-contouring services.
-
Other legally authorized clinical procedures.
Each service is subject to provider qualification, patient eligibility, equipment requirements, applicable regulations, and any necessary separate consent.
8.3 Exosome and Investigational Services
Exosome administration and investigational interventions are not authorized by this Master Agreement.
SECTION 9: FINANCIAL TERMS AND REFUND POLICY
9.1 Financial Responsibility
I understand that I am responsible for applicable charges disclosed to me for consultations, programs, laboratory testing, medications, procedures, and follow-up services.
9.2 Insurance Coverage
Insurance coverage varies by plan, service, diagnosis, medication, and applicable payer rules.
PharmXHealthOne does not guarantee insurance reimbursement.
I may request information about estimated charges and payment responsibilities before receiving services.
9.3 Refunds and Cancellations
Refunds and cancellations are governed by the written policy disclosed to me before purchase, subject to applicable consumer-protection laws and other legal requirements.
Any applicable non-refundable charge, including charges for completed services, laboratory processing, or pharmacy fulfillment, must be disclosed before the relevant financial commitment.
Nothing in this Agreement waives rights that cannot lawfully be waived.
9.4 Pricing Changes
PharmXHealthOne may modify future pricing with appropriate notice.
Pricing changes will not retroactively alter completed transactions or existing binding payment arrangements except as legally permitted.
9.5 Financial Consent
I understand that consent to medical care is separate from authorization for specific financial transactions.
SECTION 10: WITHDRAWAL AND TERMINATION OF CARE
I may withdraw consent to treatment at any time.
I understand that withdrawing consent may affect the availability or continuation of certain services.
PharmXHealthOne may decline, suspend, or discontinue nonemergency services when:
-
Continued treatment is clinically inappropriate.
-
Necessary safety monitoring cannot be completed.
-
Material medical information is inaccurate or withheld.
-
The proposed treatment is prohibited by applicable law.
-
Serious conduct or safety concerns interfere with care.
-
Other lawful grounds justify termination.
When a provider-patient relationship has been established, termination will be handled in accordance with applicable professional obligations, including reasonable notice, continuity-of-care considerations, and appropriate emergency or transition arrangements.
SECTION 11: PRIVACY, HIPAA, AND ELECTRONIC COMMUNICATION
11.1 Privacy Practices
I acknowledge that PharmXHealthOne maintains a Notice of Privacy Practices describing how protected health information may be used and disclosed and explaining applicable patient privacy rights.
I understand that accepting this Agreement does not waive my HIPAA rights.
11.2 Electronic Communication
I agree to receive appropriate communications concerning appointments, treatment coordination, and healthcare operations through the communication methods I authorize.
I understand that ordinary email and text messaging may carry privacy risks.
Where required, separate authorization or communication preferences will be obtained.
11.3 Marketing Communications
I understand that consenting to treatment does not automatically authorize promotional text messages, marketing emails, testimonial publication, or the use of my protected health information for marketing.
Any required marketing or testimonial authorization will be obtained separately.
11.4 Patient Records
I understand that medical records will be maintained and made available in accordance with applicable federal and state requirements.
SECTION 12: PATIENT SAFETY, RESPONSIBILITY, AND LEGAL RIGHTS
I understand that safe treatment requires accurate medical information, appropriate monitoring, and adherence to agreed treatment instructions.
I acknowledge that misuse of medications, unauthorized dose changes, or withholding significant medical information may increase the risk of harm.
I also understand that healthcare providers remain responsible for meeting applicable professional standards of care.
Nothing in this Agreement releases PharmXHealthOne or its clinicians from liability for negligence, professional misconduct, or other responsibilities that cannot lawfully be waived.
This Agreement does not require me to indemnify PharmXHealthOne or surrender statutory patient rights.
SECTION 13: ACKNOWLEDGMENT OF UNDERSTANDING
By electronically accepting this Agreement through an authorized patient consent process, I acknowledge that:
-
I have read this Agreement or have had it explained to me in a language and manner I understand.
-
I have had the opportunity to ask questions and receive answers.
-
I understand the general risks, benefits, alternatives, and limitations of the services discussed.
-
I understand that treatment recommendations depend on individualized clinical evaluation.
-
I understand that compounded medications are not FDA-approved.
-
I understand that investigational or unapproved substances are not automatically available or authorized for treatment.
-
I understand that no FDA-approved exosome products currently exist.
-
I understand that this Agreement does not authorize every future medication or procedure.
-
I understand that additional informed consent may be required for specific treatments.
-
I understand that no particular treatment outcome is guaranteed.
-
I understand that I may decline or withdraw consent, subject to applicable legal and clinical considerations.
-
I voluntarily consent to the applicable general healthcare evaluation and services described in this Agreement.
PharmXHealthOne
Boynton Beach, Florida
Phone: (561) 778-8121
Email: health@pharmxhealthone.com
Website: www.pharmxhealthone.com
Document Version 2.0 | November 9, 2026
Pending clinical approval by Dr. Rolando Alvarez and legal approval by Florida healthcare counsel.
MASTER CONSENT TO MEDICAL CARE
For PharmXHealthOne® Patients in FLORIDA • GEORGIA • MICHIGAN • ARIZONA
Supervising/Attending Physician:
Dr. Rolando Alvarez, MD, MS
Licensed in: Florida, Georgia, Michigan, Arizona
1. Purpose of This Consent
This document authorizes PharmXHealthOne®, its physicians, nurse practitioners,
physician associates, medical staff, contractors, and affiliates (“the Practice”) to evaluate,
treat, monitor, and medically manage you in accordance with the laws and telehealth
regulations of Florida, Georgia, Michigan, and Arizona. You are voluntarily consenting to
receive medical care—either in person or through telehealth—under the applicable state
statutes governing medical practice and patient consent.
2. Consent to Evaluation & Medical Treatment
You authorize the Practice to provide medical services including, but not limited to: medical
exams, diagnosis, treatment planning, weight management therapies, GLP-1s, peptides,
hormone therapy, labs, diagnostics, preventive and regenerative medical care. No
guarantees regarding outcomes are made.
3. Telehealth Consent (All Four States)
You consent to the use of telehealth under Florida Stat. 456.47, Georgia Telehealth Act,
Michigan PA 97 of 2020, and Arizona ARS 36-3601–3605. Telehealth may include video,
audio, messaging, and remote monitoring. Limitations include technology failures, limited
physical exam, and reliance on your self-reporting. You may withdraw telehealth at any
time.
4. State-Required Disclosures
FLORIDA: Standard of care is identical to in-person; controlled substances restricted under
456.47.
GEORGIA: Consent recognized under GA Code 31-33-8; PDMP participation required.
MICHIGAN: Telemedicine permitted; PDMP (MAPS) applies.
ARIZONA: Telehealth fully permitted; same standard of care applies.
5. Risks, Benefits & Alternatives
Risks include medication side effects, allergic reactions, complications, and telehealth
limitations. Benefits may include improved metabolic health, weight loss, symptom
reduction, hormonal balance, and prevention. Alternatives include lifestyle modifications or
in-person care.
6. Laboratory Testing & Diagnostics
You authorize ordering and interpretation of labs, hormone panels, metabolic panels, and
diagnostics.
7. Prescription Policies
A valid patient–provider relationship is required. PDMP rules apply in all four states. Misuse
or diversion results in termination. Refills require clinical review.
8. Emergency Disclaimer
PharmXHealthOne does NOT provide emergency services. Call 911 for chest pain, difficulty
breathing, severe allergic reactions, stroke symptoms, or suicidal thoughts.
9. Use & Disclosure of Health Information
You authorize use and disclosure of health information for treatment, pharmacy,
diagnostics, billing, care coordination, and compliance. HIPAA and state privacy laws apply.
10. Financial Responsibility
You agree that PharmXHealthOne may operate on a direct-pay model. Insurance may not
reimburse services or prescriptions. You are financially responsible for charges incurred.
11. Patient Responsibilities
Provide accurate history, follow treatment instructions, report reactions, attend follow-ups,
avoid misuse of medications, and update contact information.
12. Right to Withdraw Consent
You may withdraw consent at any time but remain responsible for charges already
incurred.
13. Acknowledgment
By accepting our services and treatements, you acknowledge understanding and accepting this consent for care under FL, GA, MI, and AZ laws—including telehealth consent and treatment authorization.
